

Arsen Ristic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2736265/publications.pdf>

Version: 2024-02-01

89
papers

9,222
citations

186209

28
h-index

54882

84
g-index

99
all docs

99
docs citations

99
times ranked

9040
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.0	25
2	Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. <i>Circulation</i> , 2022, 145, 648-658.	1.6	130
3	Feasibility of the cardiac output response to stress test in suspected heart failure patients. <i>Family Practice</i> , 2022, ,	0.8	1
4	Education and certification on heart failure of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	2.9	6
5	Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathyâ€”An Analysis from the SILICOFCM Database. <i>Medicina (Lithuania)</i> , 2022, 58, 314.	0.8	10
6	Cardiac remodellingâ€”Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
7	Cardiomyopathies: Classification, diagnosis and treatment modalities. , 2022, 1, 38-48.		0
8	Acute Coronary Syndrome in the COVID-19 Eraâ€”Differences and Dilemmas Compared to the Pre-COVID-19 Era. <i>Journal of Clinical Medicine</i> , 2022, 11, 3024.	1.0	11
9	Insights into heart failure hospitalizations, management, and services during and beyond COVIDâ€™19. <i>ESC Heart Failure</i> , 2021, 8, 175-182.	1.4	22
10	<sc>H₂</sc>FPEF</sc> score predicts atherosclerosis presence in patients with systemic connective tissue disease. <i>Clinical Cardiology</i> , 2021, 44, 946-954.	0.7	2
11	Guidance on the management of left ventricular assist device <sc>(LVAD)</sc> supported patients for the nonâ€left ventricular assist device specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
12	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€supported patients for the nonâ€left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
13	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the nonâ€hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
14	HFA of the ESC position paper on the management of LVADâ€supported patients for the nonâ€LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
15	<sc>COVID</sc>â€™19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
16	Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2021, 10, e021936.	1.6	12
17	Cardiovascular diagnosis in patients with rheumatoid arthritis, primary SjÃ¶gren's syndrome, systemic sclerosis and systemic lupus erythematosus. <i>Medicinski Podmladak</i> , 2021, 72, 1-7.	0.2	0
18	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 516.	0.7	33

#	ARTICLE	IF	CITATIONS
19	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. <i>Clinical Cardiology</i> , 2020, 43, 430-440.	0.7	15
20	Ventricular arrhythmias not meeting criteria for terminating cardiopulmonary exercise testing stratify prognosis and disease severity in heart failure of preserved, midrange, and reduced ejection fraction. <i>Clinical Cardiology</i> , 2020, 43, 698-705.	0.7	1
21	N-Terminal-pro-Brain natriuretic peptide dynamics during effort phenotypes ischemic heart failure and determines prognosis regardless of ejection fraction. <i>Peptides</i> , 2020, 129, 170315.	1.2	1
22	Comparison of Custodiol® and modified St. Thomas cardioplegia for myocardial protection in coronary artery bypass grafting. <i>Vojnosanitetski Pregled</i> , 2020, 77, 1126-1134.	0.1	0
23	Correlation between central venous and mixed venous oxygen saturation in the elective abdominal aortic aneurysm surgery. <i>Vojnosanitetski Pregled</i> , 2020, 77, 697-703.	0.1	0
24	Glutathione Transferase P1 Polymorphism Might Be a Risk Determinant in Heart Failure. <i>Disease Markers</i> , 2019, 2019, 1-11.	0.6	20
25	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. <i>European Respiratory Journal</i> , 2019, 54, 1901030.	3.1	33
26	Association between heart rate variability and haemodynamic response to exercise in chronic heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 77-82.	0.4	4
27	Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 72-82.	0.8	27
28	Streptococcus Gallolyticus endocarditis in patient with liver cirrhosis: a case report. <i>Journal of Infection in Developing Countries</i> , 2019, 13, 352-356.	0.5	1
29	A systematic review of the efficacy and safety of intrapericardial fibrinolysis in patients with pericardial effusion. <i>International Journal of Cardiology</i> , 2018, 250, 223-228.	0.8	20
30	Successful establishment of a left ventricular assist device program in an emerging country: one year experience. <i>Journal of Thoracic Disease</i> , 2018, 10, S1743-S1750.	0.6	4
31	A novel cardiac output response to stress test developed to improve diagnosis and monitoring of heart failure in primary care. <i>ESC Heart Failure</i> , 2018, 5, 703-712.	1.4	11
32	Fixed combination of bisoprolol and a low-dose hydrochlorothiazide in arterial hypertension. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2018, 146, 330-337.	0.1	0
33	HeartMate 3 fully magnetically levitated left ventricular assist device for advanced heart failure: Initial Serbian experience. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2018, 146, 584-587.	0.1	0
34	N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy. <i>Journal of Cardiology</i> , 2017, 70, 323-328.	0.8	25
35	Percutaneous Therapy in Pericardial Diseases. <i>Cardiology Clinics</i> , 2017, 35, 567-588.	0.9	20
36	P4665 Impact of the combined anemia and impaired left ventricular function on long-term outcome in STEMI patients undergoing primary PC. <i>European Heart Journal</i> , 2017, 38, .	1.0	0

#	ARTICLE	IF	CITATIONS
37	P3266 Differential impact of impaired renal function and acute heart failure on short- and long-term mortality in patients undergoing primary PCI for STEMI. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
38	Prevalence of high on-treatment platelet reactivity in patients after percutaneous coronary intervention. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 282-285.	0.4	3
39	Exercise capacity is not impaired after acute alcohol ingestion. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 896-901.	0.6	2
40	Management and Outcome of Periprocedural Cardiac Perforation and Tamponade with Radiofrequency Catheter Ablation of Cardiac Arrhythmias: A Single Medium-Volume Center Experience. <i>Advances in Therapy</i> , 2016, 33, 1782-1796.	1.3	23
41	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	2.9	455
42	Diabetes mellitus and coronary microvascular function in asymptomatic patients with severe aortic stenosis and nonobstructed coronary arteries. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 220-227.	0.9	10
43	Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic severe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. <i>American Heart Journal</i> , 2016, 174, 147-153.	1.2	55
44	Acute renal failure and hepatocellular damage as presenting symptoms of type II aortic dissection. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2016, 144, 320-324.	0.1	0
45	The effects of implementation of guideline-directed medical therapy on relief of angina in patients with stable coronary artery disease in Serbia. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2016, 144, 590-596.	0.1	0
46	Differential diagnosis and management of chronic pericarditis in the context of 2015 ESC guidelines on pericardial diseases. <i>Srce I Krvni Sudovi</i> , 2016, 35, 32-35.	0.1	0
47	Timing of invasive strategy in NSTEMI-ACS patients and effect on clinical outcomes: A systematic review and meta-analysis of randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 48-54.	0.4	39
48	Mineralocorticoid receptor antagonists, a class beyond spironolactone – Focus on the special pharmacologic properties of eplerenone. <i>International Journal of Cardiology</i> , 2015, 200, 3-7.	0.8	17
49	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. <i>European Heart Journal</i> , 2015, 36, 2921-2964.	1.0	1,768
50	European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 12-31.	0.5	186
51	Valvulo-arterial impedance is the best mortality predictor in asymptomatic aortic stenosis patients. <i>Journal of Heart Valve Disease</i> , 2015, 24, 156-63.	0.5	9
52	Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1016.	3.8	258
53	The role of glycemia in acute heart failure patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1437-46.	1.4	4
54	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2014, 35, 2279-2284.	1.0	154

#	ARTICLE	IF	CITATIONS
55	Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. <i>Cardiovascular Diabetology</i> , 2014, 13, 73.	2.7	37
56	How does stress possibly affect cardiac remodeling?. <i>Peptides</i> , 2014, 57, 20-30.	1.2	5
57	The interface of hypothalamicâ€“pituitaryâ€“adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress. <i>Peptides</i> , 2013, 47, 85-93.	1.2	15
58	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2013, 34, 1448-1458.	1.0	346
59	Pericardial syndromes: an update after the ESC guidelines 2004. <i>Heart Failure Reviews</i> , 2013, 18, 255-266.	1.7	77
60	Epicardial halo phenomenon: a guide for pericardiocentesis?. <i>Heart Failure Reviews</i> , 2013, 18, 307-316.	1.7	26
61	Pericardial cytokines in neoplastic, autoreactive, and viral pericarditis. <i>Heart Failure Reviews</i> , 2013, 18, 345-353.	1.7	42
62	Pericardioscopy and epi- and pericardial biopsyâ€“a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. <i>Heart Failure Reviews</i> , 2013, 18, 317-328.	1.7	62
63	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2013, 34, 2636-2648.	1.0	2,436
64	Mitral valve endocarditis during brucellosis relapse. <i>Vojnosanitetski Pregled</i> , 2012, 69, 725-729.	0.1	1
65	Diabetic cardiomyopathy: ongoing controversies in 2012. <i>Herz</i> , 2012, 37, 880-886.	0.4	19
66	Preoperative and perioperative management of patients with pericardial diseases. <i>Acta Chirurgica Iugoslavica</i> , 2011, 58, 45-53.	0.0	3
67	Asymptomatic cardiovascular manifestations in diabetes mellitus: Left ventricular diastolic dysfunction and silent myocardial ischemia. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2011, 139, 599-604.	0.1	4
68	Heart tamponade caused by coronary artery rupture during PCI. <i>Srce I Krvni Sudovi</i> , 2011, 30, 55-59.	0.1	0
69	Evaluation and Management of Pericardial Effusion in Patients with Neoplastic Disease. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 157-163.	1.6	125
70	Multimodality Imaging in the Assessment of Cardiac Lymphoma Presented as Newâ€“Onset Atrial Fibrillation. <i>Echocardiography</i> , 2010, 27, 332-336.	0.3	5
71	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2010, 31, 2715-2726.	1.0	408
72	Pathogenesis, diagnosis and treatment of pericarditis. , 2010, , 3-24.		0

#	ARTICLE	IF	CITATIONS
73	Magnetic Resonance Imaging in Pericardial Diseases. Herz, 2006, 31, 708-714.	0.4	27
74	Bacterial Pericarditis. American Journal of Cardiovascular Drugs, 2005, 5, 103-112.	1.0	131
75	Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. European Heart Journal, 2004, 25, 587-610.	1.0	1,127
76	Pericardial Disease in Pregnancy. Herz, 2003, 28, 209-215.	0.4	44
77	Human viral cardiomyopathy. Frontiers in Bioscience - Landmark, 2003, 8, s39-67.	3.0	43
78	Intrapericardial treatment of autoreactive pericardial effusion with triamcinolone. The way to avoid side effects of systemic corticosteroid therapy. European Heart Journal, 2002, 23, 1503-1508.	1.0	155
79	Pathophysiology of viral myocarditis. Cardiovascular Pathology, 2002, 11, 112-122.	0.7	64
80	The classification of pericardial disease in the age of modern medicine. Current Cardiology Reports, 2002, 4, 13-21.	1.3	57
81	Dilated Cardiomyopathies as a Cause of Congestive Heart Failure. Herz, 2002, 27, 113-134.	0.4	27
82	Immunological basis of the cardiac conduction and rhythm disorders. European Heart Journal, 2001, 22, 813-824.	1.0	21
83	Pericardial access using the perDUCER and flexible percutaneous pericardioscopy. American Journal of Cardiology, 2001, 88, 1323-1326.	0.7	42
84	Arrhythmias in Acute Pericarditis An Endomyocardial Biopsy Study. Herz, 2000, 25, 729-733.	0.4	18
85	Flexible Percutaneous Pericardioscopy: Inherent Drawbacks and Recent Advances. Herz, 2000, 25, 741-747.	0.4	14
86	New Directions in Diagnosis and Treatment of Pericardial Disease A Project of the Taskforce on Pericardial Disease of the World Heart Federation. Herz, 2000, 25, 769-780.	0.4	21
87	Intrapericardial Treatment of Autoreactive Myocarditis with Triamcinolon Successful Administration in Patients with Minimal Pericardial Effusion. Herz, 2000, 25, 781-786.	0.4	23
88	Cardiac Rhythm and Conduction Disturbances: What is the Role of Autoimmune Mechanisms?. Herz, 2000, 25, 181-188.	0.4	16
89	Definition of Inflammatory Cardiomyopathy (Myocarditis): On the Way to Consensus. Herz, 2000, 25, 200-209.	0.4	155